

PE Anti-Human CD178 (Fas ligand) (NOK-1) Antibody
Catalog # ATB10422**Specification****PE Anti-Human CD178 (Fas ligand) (NOK-1) Antibody - Product Information**

Application	FC
Isotype	Mouse IgG1, kappa
Concentration	5ul(0.5ug)/test
Reactivity	Human
Formulation	10mM NaH ₂ PO ₄ , 150 mM NaCl, 0.09% NaN ₃ , 0.1% gelatin, pH7.2

PE Anti-Human CD178 (Fas ligand) (NOK-1) Antibody - Additional Information

Gene ID	356
Gene Name	FASLG
Alternative Name(s)	
CD95L, Fas ligand, FasL	

Format

PE


Storage Conditions


2-8°C protected from light

PE Anti-Human CD178 (Fas ligand) (NOK-1) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

PE Anti-Human CD178 (Fas ligand) (NOK-1) Antibody - Images



Human CD178 (Fas ligand) transfected cells were stained with 5 uL (0.5 ug) PE Anti-Human CD178 (ATB10422) (solid line) or 0.5 ug PE Mouse IgG1 isotype control (dashed line).

PE Anti-Human CD178 (Fas ligand) (NOK-1) Antibody - Background

The NOK-1 antibody reacts with human CD178 (Fas ligand) in both membrane bound and soluble forms. Fas ligand is a 40 kDa transmembrane glycoprotein, a member of the TNF family, and is expressed by activated T and NK cells, neutrophils, and monocytes. Interactions between CD178 (Fas ligand) and CD95 (Fas) induce a program of apoptosis and play a key role in immune regulation and homeostasis. The extracellular domain of human CD178 can be cleaved from the surface by matrix metalloproteinases (MMPs) resulting in a 26 kDa soluble protein.

PE Anti-Human CD178 (Fas ligand) (NOK-1) Antibody - References

Tanaka M, Suda T, Takahashi T, and Nagata S. 1995. EMBO J. 14(6):1129-1135.

Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, and Yagita H. 1995. J Exp Med. 182(6):1777-1783.

Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. 1997. J Exp Med. 186(12):2045-2050.

Ehrenschwender M, Wajant H. 2009. Adv Exp Med Biol. 647:64-93.